 Global Inhaled Medicines for Respiratory System Market Growth 2026-2032
The global Inhaled Medicines for Respiratory System market size is predicted to grow from US$ 11630 million in 2025 to US$ 14810 million in 2032; it is expected to grow at a CAGR of 3.6% from 2026 ... もっと見る
英語原文をAIを使って翻訳しています。
図表リストList of TablesTable 1. Inhaled Medicines for Respiratory System Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions) Table 2. Inhaled Medicines for Respiratory System Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions) Table 3. Major Players of Inhaled Corticosteroids Table 4. Major Players of Long-acting Bronchodilators Table 5. Major Players of Short-acting Bronchodilators Table 6. Major Players of Combination Medications Table 7. Global Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 8. Global Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) Table 9. Global Inhaled Medicines for Respiratory System Revenue by Type (2021-2026) & ($ million) Table 10. Global Inhaled Medicines for Respiratory System Revenue Market Share by Type (2021-2026) Table 11. Global Inhaled Medicines for Respiratory System Sale Price by Type (2021-2026) & (US$/Unit) Table 12. Global Inhaled Medicines for Respiratory System Sale by Application (2021-2026) & (K Units) Table 13. Global Inhaled Medicines for Respiratory System Sale Market Share by Application (2021-2026) Table 14. Global Inhaled Medicines for Respiratory System Revenue by Application (2021-2026) & ($ million) Table 15. Global Inhaled Medicines for Respiratory System Revenue Market Share by Application (2021-2026) Table 16. Global Inhaled Medicines for Respiratory System Sale Price by Application (2021-2026) & (US$/Unit) Table 17. Global Inhaled Medicines for Respiratory System Sales by Company (2021-2026) & (K Units) Table 18. Global Inhaled Medicines for Respiratory System Sales Market Share by Company (2021-2026) Table 19. Global Inhaled Medicines for Respiratory System Revenue by Company (2021-2026) & ($ millions) Table 20. Global Inhaled Medicines for Respiratory System Revenue Market Share by Company (2021-2026) Table 21. Global Inhaled Medicines for Respiratory System Sale Price by Company (2021-2026) & (US$/Unit) Table 22. Key Manufacturers Inhaled Medicines for Respiratory System Producing Area Distribution and Sales Area Table 23. Players Inhaled Medicines for Respiratory System Products Offered Table 24. Inhaled Medicines for Respiratory System Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) Table 25. New Products and Potential Entrants Table 26. Market M&A Activity & Strategy Table 27. Global Inhaled Medicines for Respiratory System Sales by Geographic Region (2021-2026) & (K Units) Table 28. Global Inhaled Medicines for Respiratory System Sales Market Share Geographic Region (2021-2026) Table 29. Global Inhaled Medicines for Respiratory System Revenue by Geographic Region (2021-2026) & ($ millions) Table 30. Global Inhaled Medicines for Respiratory System Revenue Market Share by Geographic Region (2021-2026) Table 31. Global Inhaled Medicines for Respiratory System Sales by Country/Region (2021-2026) & (K Units) Table 32. Global Inhaled Medicines for Respiratory System Sales Market Share by Country/Region (2021-2026) Table 33. Global Inhaled Medicines for Respiratory System Revenue by Country/Region (2021-2026) & ($ millions) Table 34. Global Inhaled Medicines for Respiratory System Revenue Market Share by Country/Region (2021-2026) Table 35. Americas Inhaled Medicines for Respiratory System Sales by Country (2021-2026) & (K Units) Table 36. Americas Inhaled Medicines for Respiratory System Sales Market Share by Country (2021-2026) Table 37. Americas Inhaled Medicines for Respiratory System Revenue by Country (2021-2026) & ($ millions) Table 38. Americas Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 39. Americas Inhaled Medicines for Respiratory System Sales by Application (2021-2026) & (K Units) Table 40. APAC Inhaled Medicines for Respiratory System Sales by Region (2021-2026) & (K Units) Table 41. APAC Inhaled Medicines for Respiratory System Sales Market Share by Region (2021-2026) Table 42. APAC Inhaled Medicines for Respiratory System Revenue by Region (2021-2026) & ($ millions) Table 43. APAC Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 44. APAC Inhaled Medicines for Respiratory System Sales by Application (2021-2026) & (K Units) Table 45. Europe Inhaled Medicines for Respiratory System Sales by Country (2021-2026) & (K Units) Table 46. Europe Inhaled Medicines for Respiratory System Revenue by Country (2021-2026) & ($ millions) Table 47. Europe Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 48. Europe Inhaled Medicines for Respiratory System Sales by Application (2021-2026) & (K Units) Table 49. Middle East & Africa Inhaled Medicines for Respiratory System Sales by Country (2021-2026) & (K Units) Table 50. Middle East & Africa Inhaled Medicines for Respiratory System Revenue Market Share by Country (2021-2026) Table 51. Middle East & Africa Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 52. Middle East & Africa Inhaled Medicines for Respiratory System Sales by Application (2021-2026) & (K Units) Table 53. Key Market Drivers & Growth Opportunities of Inhaled Medicines for Respiratory System Table 54. Key Market Challenges & Risks of Inhaled Medicines for Respiratory System Table 55. Key Industry Trends of Inhaled Medicines for Respiratory System Table 56. Inhaled Medicines for Respiratory System Raw Material Table 57. Key Suppliers of Raw Materials Table 58. Inhaled Medicines for Respiratory System Distributors List Table 59. Inhaled Medicines for Respiratory System Customer List Table 60. Global Inhaled Medicines for Respiratory System Sales Forecast by Region (2027-2032) & (K Units) Table 61. Global Inhaled Medicines for Respiratory System Revenue Forecast by Region (2027-2032) & ($ millions) Table 62. Americas Inhaled Medicines for Respiratory System Sales Forecast by Country (2027-2032) & (K Units) Table 63. Americas Inhaled Medicines for Respiratory System Annual Revenue Forecast by Country (2027-2032) & ($ millions) Table 64. APAC Inhaled Medicines for Respiratory System Sales Forecast by Region (2027-2032) & (K Units) Table 65. APAC Inhaled Medicines for Respiratory System Annual Revenue Forecast by Region (2027-2032) & ($ millions) Table 66. Europe Inhaled Medicines for Respiratory System Sales Forecast by Country (2027-2032) & (K Units) Table 67. Europe Inhaled Medicines for Respiratory System Revenue Forecast by Country (2027-2032) & ($ millions) Table 68. Middle East & Africa Inhaled Medicines for Respiratory System Sales Forecast by Country (2027-2032) & (K Units) Table 69. Middle East & Africa Inhaled Medicines for Respiratory System Revenue Forecast by Country (2027-2032) & ($ millions) Table 70. Global Inhaled Medicines for Respiratory System Sales Forecast by Type (2027-2032) & (K Units) Table 71. Global Inhaled Medicines for Respiratory System Revenue Forecast by Type (2027-2032) & ($ millions) Table 72. Global Inhaled Medicines for Respiratory System Sales Forecast by Application (2027-2032) & (K Units) Table 73. Global Inhaled Medicines for Respiratory System Revenue Forecast by Application (2027-2032) & ($ millions) Table 74. Boehringer Ingelheim Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 75. Boehringer Ingelheim Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 76. Boehringer Ingelheim Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Boehringer Ingelheim Main Business Table 78. Boehringer Ingelheim Latest Developments Table 79. GSK Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 80. GSK Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 81. GSK Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. GSK Main Business Table 83. GSK Latest Developments Table 84. Teva Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 85. Teva Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 86. Teva Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Teva Pharmaceutical Main Business Table 88. Teva Pharmaceutical Latest Developments Table 89. Prasco Laboratories Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 90. Prasco Laboratories Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 91. Prasco Laboratories Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Prasco Laboratories Main Business Table 93. Prasco Laboratories Latest Developments Table 94. Cipla Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 95. Cipla Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 96. Cipla Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Cipla Main Business Table 98. Cipla Latest Developments Table 99. Lupin Laboratories Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 100. Lupin Laboratories Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 101. Lupin Laboratories Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Lupin Laboratories Main Business Table 103. Lupin Laboratories Latest Developments Table 104. Laboratorio Aldo-Union Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 105. Laboratorio Aldo-Union Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 106. Laboratorio Aldo-Union Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Laboratorio Aldo-Union Main Business Table 108. Laboratorio Aldo-Union Latest Developments Table 109. Polpharma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 110. Polpharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 111. Polpharma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Polpharma Main Business Table 113. Polpharma Latest Developments Table 114. Novartis Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 115. Novartis Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 116. Novartis Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Novartis Main Business Table 118. Novartis Latest Developments Table 119. The Menarini Group Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 120. The Menarini Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 121. The Menarini Group Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. The Menarini Group Main Business Table 123. The Menarini Group Latest Developments Table 124. Covis Pharma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 125. Covis Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 126. Covis Pharma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Covis Pharma Main Business Table 128. Covis Pharma Latest Developments Table 129. Zentiva Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 130. Zentiva Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 131. Zentiva Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Zentiva Main Business Table 133. Zentiva Latest Developments Table 134. Alfasigma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 135. Alfasigma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 136. Alfasigma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Alfasigma Main Business Table 138. Alfasigma Latest Developments Table 139. Gebro-Pharma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 140. Gebro-Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 141. Gebro-Pharma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Gebro-Pharma Main Business Table 143. Gebro-Pharma Latest Developments Table 144. Kohl Medical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 145. Kohl Medical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 146. Kohl Medical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Kohl Medical Main Business Table 148. Kohl Medical Latest Developments Table 149. Sumitomo Pharma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 150. Sumitomo Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 151. Sumitomo Pharma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Sumitomo Pharma Main Business Table 153. Sumitomo Pharma Latest Developments Table 154. Chiesi Farmaceutici Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 155. Chiesi Farmaceutici Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 156. Chiesi Farmaceutici Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Chiesi Farmaceutici Main Business Table 158. Chiesi Farmaceutici Latest Developments Table 159. Glenmark Pharmaceuticals Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 160. Glenmark Pharmaceuticals Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 161. Glenmark Pharmaceuticals Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Glenmark Pharmaceuticals Main Business Table 163. Glenmark Pharmaceuticals Latest Developments Table 164. Orion Corporation Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 165. Orion Corporation Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 166. Orion Corporation Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Orion Corporation Main Business Table 168. Orion Corporation Latest Developments Table 169. Bausch Health Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 170. Bausch Health Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 171. Bausch Health Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Bausch Health Main Business Table 173. Bausch Health Latest Developments Table 174. Viatris Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 175. Viatris Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 176. Viatris Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Viatris Main Business Table 178. Viatris Latest Developments Table 179. AstraZeneca Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 180. AstraZeneca Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 181. AstraZeneca Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. AstraZeneca Main Business Table 183. AstraZeneca Latest Developments Table 184. LEK-AM Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 185. LEK-AM Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 186. LEK-AM Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 187. LEK-AM Main Business Table 188. LEK-AM Latest Developments Table 189. Adamed Group Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 190. Adamed Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 191. Adamed Group Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 192. Adamed Group Main Business Table 193. Adamed Group Latest Developments Table 194. STADA Arzneimittel Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 195. STADA Arzneimittel Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 196. STADA Arzneimittel Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 197. STADA Arzneimittel Main Business Table 198. STADA Arzneimittel Latest Developments Table 199. Organon Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 200. Organon Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 201. Organon Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 202. Organon Main Business Table 203. Organon Latest Developments Table 204. Anhui Wellman Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 205. Anhui Wellman Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 206. Anhui Wellman Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 207. Anhui Wellman Pharmaceutical Main Business Table 208. Anhui Wellman Pharmaceutical Latest Developments Table 209. Zhejiang Xianjun Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 210. Zhejiang Xianjun Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 211. Zhejiang Xianjun Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 212. Zhejiang Xianjun Pharmaceutical Main Business Table 213. Zhejiang Xianjun Pharmaceutical Latest Developments Table 214. Chia Tai Tianqing Pharmaceutical Group Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 215. Chia Tai Tianqing Pharmaceutical Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 216. Chia Tai Tianqing Pharmaceutical Group Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 217. Chia Tai Tianqing Pharmaceutical Group Main Business Table 218. Chia Tai Tianqing Pharmaceutical Group Latest Developments Table 219. Nanchang Helioeast Technology Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 220. Nanchang Helioeast Technology Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 221. Nanchang Helioeast Technology Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 222. Nanchang Helioeast Technology Main Business Table 223. Nanchang Helioeast Technology Latest Developments Table 224. Jewim Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 225. Jewim Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 226. Jewim Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 227. Jewim Pharmaceutical Main Business Table 228. Jewim Pharmaceutical Latest Developments Table 229. Heilongjiang Fulekang Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 230. Heilongjiang Fulekang Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 231. Heilongjiang Fulekang Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 232. Heilongjiang Fulekang Pharmaceutical Main Business Table 233. Heilongjiang Fulekang Pharmaceutical Latest Developments Table 234. Shanghai Pharmaceuticals Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 235. Shanghai Pharmaceuticals Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 236. Shanghai Pharmaceuticals Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 237. Shanghai Pharmaceuticals Main Business Table 238. Shanghai Pharmaceuticals Latest Developments Table 239. Lunan Better Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 240. Lunan Better Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 241. Lunan Better Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 242. Lunan Better Pharmaceutical Main Business Table 243. Lunan Better Pharmaceutical Latest Developments Table 244. China Resources Double Crane Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 245. China Resources Double Crane Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 246. China Resources Double Crane Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 247. China Resources Double Crane Pharmaceutical Main Business Table 248. China Resources Double Crane Pharmaceutical Latest Developments List of Figures Figure 1. Picture of Inhaled Medicines for Respiratory System Figure 2. Inhaled Medicines for Respiratory System Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Inhaled Medicines for Respiratory System Sales Growth Rate 2021-2032 (K Units) Figure 7. Global Inhaled Medicines for Respiratory System Revenue Growth Rate 2021-2032 ($ millions) Figure 8. Inhaled Medicines for Respiratory System Sales by Geographic Region (2021, 2025 & 2032) & ($ millions) Figure 9. Inhaled Medicines for Respiratory System Sales Market Share by Country/Region (2025) Figure 10. Inhaled Medicines for Respiratory System Sales Market Share by Country/Region (2021, 2025 & 2032) Figure 11. Product Picture of Inhaled Corticosteroids Figure 12. Product Picture of Long-acting Bronchodilators Figure 13. Product Picture of Short-acting Bronchodilators Figure 14. Product Picture of Combination Medications Figure 15. Global Inhaled Medicines for Respiratory System Sales Market Share by Type in 2026 Figure 16. Global Inhaled Medicines for Respiratory System Revenue Market Share by Type (2021-2026) Figure 17. Inhaled Medicines for Respiratory System Consumed in Asthma Figure 18. Global Inhaled Medicines for Respiratory System Market: Asthma (2021-2026) & (K Units) Figure 19. Inhaled Medicines for Respiratory System Consumed in COPD Figure 20. Global Inhaled Medicines for Respiratory System Market: COPD (2021-2026) & (K Units) Figure 21. Inhaled Medicines for Respiratory System Consumed in Others Figure 22. Global Inhaled Medicines for Respiratory System Market: Others (2021-2026) & (K Units) Figure 23. Global Inhaled Medicines for Respiratory System Sale Market Share by Application (2025) Figure 24. Global Inhaled Medicines for Respiratory System Revenue Market Share by Application in 2026 Figure 25. Inhaled Medicines for Respiratory System Sales by Company in 2026 (K Units) Figure 26. Global Inhaled Medicines for Respiratory System Sales Market Share by Company in 2026 Figure 27. Inhaled Medicines for Respiratory System Revenue by Company in 2026 ($ millions) Figure 28. Global Inhaled Medicines for Respiratory System Revenue Market Share by Company in 2026 Figure 29. Global Inhaled Medicines for Respiratory System Sales Market Share by Geographic Region (2021-2026) Figure 30. Global Inhaled Medicines for Respiratory System Revenue Market Share by Geographic Region in 2026 Figure 31. Americas Inhaled Medicines for Respiratory System Sales 2021-2026 (K Units) Figure 32. Americas Inhaled Medicines for Respiratory System Revenue 2021-2026 ($ millions) Figure 33. APAC Inhaled Medicines for Respiratory System Sales 2021-2026 (K Units) Figure 34. APAC Inhaled Medicines for Respiratory System Revenue 2021-2026 ($ millions) Figure 35. Europe Inhaled Medicines for Respiratory System Sales 2021-2026 (K Units) Figure 36. Europe Inhaled Medicines for Respiratory System Revenue 2021-2026 ($ millions) Figure 37. Middle East & Africa Inhaled Medicines for Respiratory System Sales 2021-2026 (K Units) Figure 38. Middle East & Africa Inhaled Medicines for Respiratory System Revenue 2021-2026 ($ millions) Figure 39. Americas Inhaled Medicines for Respiratory System Sales Market Share by Country in 2026 Figure 40. Americas Inhaled Medicines for Respiratory System Revenue Market Share by Country (2021-2026) Figure 41. Americas Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) Figure 42. Americas Inhaled Medicines for Respiratory System Sales Market Share by Application (2021-2026) Figure 43. United States Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 44. Canada Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 45. Mexico Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 46. Brazil Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 47. APAC Inhaled Medicines for Respiratory System Sales Market Share by Region in 2026 Figure 48. APAC Inhaled Medicines for Respiratory System Revenue Market Share by Region (2021-2026) Figure 49. APAC Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) Figure 50. APAC Inhaled Medicines for Respiratory System Sales Market Share by Application (2021-2026) Figure 51. China Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 52. Japan Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 53. South Korea Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 54. Southeast Asia Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 55. India Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 56. Australia Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 57. China Taiwan Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 58. Europe Inhaled Medicines for Respiratory System Sales Market Share by Country in 2026 Figure 59. Europe Inhaled Medicines for Respiratory System Revenue Market Share by Country (2021-2026) Figure 60. Europe Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) Figure 61. Europe Inhaled Medicines for Respiratory System Sales Market Share by Application (2021-2026)
SummaryThe global Inhaled Medicines for Respiratory System market size is predicted to grow from US$ 11630 million in 2025 to US$ 14810 million in 2032; it is expected to grow at a CAGR of 3.6% from 2026 to 2032.Inhaled medicines for the respiratory system are primarily used for treating asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions, including inhaled corticosteroids (ICS), short-acting and long-acting bronchodilators (SABA, LABA, LAMA), combination therapies, and novel long-acting inhaled formulations (LAIM). Upstream raw materials include active pharmaceutical ingredients (APIs), medical-grade excipients such as emulsifiers and buffers, propellants for aerosols (HFA, DME), and precision plastics, metals, and sealing components for inhalation devices. Leading suppliers such as BASF, Dow Chemical, Evonik, Samsung Pharmaceutical Ingredients, and domestic API manufacturers provide high-purity, stable materials to ensure the safety and efficacy of inhaled medicines. Downstream customers include global pharmaceutical companies, hospital respiratory departments, clinics, and chronic disease management centers. Inhaled medicines are delivered via metered-dose inhalers, dry powder inhalers, and soft mist inhalers, widely applied for both acute relief and long-term maintenance therapy. In 2024, the global average price of inhaled medicines for respiratory diseases was approximately USD 17.2 per unit, with total sales reaching around 664 million units. United States market for Inhaled Medicines for Respiratory System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. China market for Inhaled Medicines for Respiratory System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Europe market for Inhaled Medicines for Respiratory System is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032. Global key Inhaled Medicines for Respiratory System players cover Boehringer Ingelheim, GSK, Teva Pharmaceutical, Prasco Laboratories, Cipla, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025. Report Scope LP Information, Inc. (LPI) ' newest research report, the “Inhaled Medicines for Respiratory System Industry Forecast” looks at past sales and reviews total world Inhaled Medicines for Respiratory System sales in 2025, providing a comprehensive analysis by region and market sector of projected Inhaled Medicines for Respiratory System sales for 2026 through 2032. With Inhaled Medicines for Respiratory System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Inhaled Medicines for Respiratory System industry. This Insight Report provides a comprehensive analysis of the global Inhaled Medicines for Respiratory System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inhaled Medicines for Respiratory System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Inhaled Medicines for Respiratory System market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inhaled Medicines for Respiratory System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inhaled Medicines for Respiratory System. This report presents a comprehensive overview, market shares, and growth opportunities of Inhaled Medicines for Respiratory System market by product type, application, key manufacturers and key regions and countries. Market Segmentation Segmentation by Type: Inhaled Corticosteroids Long-acting Bronchodilators Short-acting Bronchodilators Combination Medications Segmentation by Application: Asthma COPD Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration. Boehringer Ingelheim GSK Teva Pharmaceutical Prasco Laboratories Cipla Lupin Laboratories Laboratorio Aldo-Union Polpharma Novartis The Menarini Group Covis Pharma Zentiva Alfasigma Gebro-Pharma Kohl Medical Sumitomo Pharma Chiesi Farmaceutici Glenmark Pharmaceuticals Orion Corporation Bausch Health Viatris AstraZeneca LEK-AM Adamed Group STADA Arzneimittel Organon Anhui Wellman Pharmaceutical Zhejiang Xianjun Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanchang Helioeast Technology Jewim Pharmaceutical Heilongjiang Fulekang Pharmaceutical Shanghai Pharmaceuticals Lunan Better Pharmaceutical China Resources Double Crane Pharmaceutical Key Questions Addressed in this Report What is the 10-year outlook for the global Inhaled Medicines for Respiratory System market? What factors are driving Inhaled Medicines for Respiratory System market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Inhaled Medicines for Respiratory System market opportunities vary by end market size? How does Inhaled Medicines for Respiratory System break out by Type, by Application? Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Inhaled Medicines for Respiratory System Annual Sales 2021-2032 2.1.2 World Current & Future Analysis for Inhaled Medicines for Respiratory System by Geographic Region, 2021, 2025 & 2032 2.1.3 World Current & Future Analysis for Inhaled Medicines for Respiratory System by Country/Region, 2021, 2025 & 2032 2.2 Inhaled Medicines for Respiratory System Segment by Type 2.2.1 Inhaled Corticosteroids 2.2.2 Long-acting Bronchodilators 2.2.3 Short-acting Bronchodilators 2.2.4 Combination Medications 2.2.5 Inhaled Medicines for Respiratory System Sales by Type 2.2.5.1 Global Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) 2.2.5.2 Global Inhaled Medicines for Respiratory System Revenue and Market Share by Type (2021-2026) 2.2.5.3 Global Inhaled Medicines for Respiratory System Sale Price by Type (2021-2026) 2.3 Inhaled Medicines for Respiratory System Segment by Application 2.3.1 Asthma 2.3.2 COPD 2.3.3 Others 2.3.4 Inhaled Medicines for Respiratory System Sales by Application 2.3.4.1 Global Inhaled Medicines for Respiratory System Sale Market Share by Application (2021-2026) 2.3.4.2 Global Inhaled Medicines for Respiratory System Revenue and Market Share by Application (2021-2026) 2.3.4.3 Global Inhaled Medicines for Respiratory System Sale Price by Application (2021-2026) 3 Global by Company 3.1 Global Inhaled Medicines for Respiratory System Breakdown Data by Company 3.1.1 Global Inhaled Medicines for Respiratory System Annual Sales by Company (2021-2026) 3.1.2 Global Inhaled Medicines for Respiratory System Sales Market Share by Company (2021-2026) 3.2 Global Inhaled Medicines for Respiratory System Annual Revenue by Company (2021-2026) 3.2.1 Global Inhaled Medicines for Respiratory System Revenue by Company (2021-2026) 3.2.2 Global Inhaled Medicines for Respiratory System Revenue Market Share by Company (2021-2026) 3.3 Global Inhaled Medicines for Respiratory System Sale Price by Company 3.4 Key Manufacturers Inhaled Medicines for Respiratory System Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Inhaled Medicines for Respiratory System Product Location Distribution 3.4.2 Players Inhaled Medicines for Respiratory System Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Inhaled Medicines for Respiratory System by Geographic Region 4.1 World Historic Inhaled Medicines for Respiratory System Market Size by Geographic Region (2021-2026) 4.1.1 Global Inhaled Medicines for Respiratory System Annual Sales by Geographic Region (2021-2026) 4.1.2 Global Inhaled Medicines for Respiratory System Annual Revenue by Geographic Region (2021-2026) 4.2 World Historic Inhaled Medicines for Respiratory System Market Size by Country/Region (2021-2026) 4.2.1 Global Inhaled Medicines for Respiratory System Annual Sales by Country/Region (2021-2026) 4.2.2 Global Inhaled Medicines for Respiratory System Annual Revenue by Country/Region (2021-2026) 4.3 Americas Inhaled Medicines for Respiratory System Sales Growth 4.4 APAC Inhaled Medicines for Respiratory System Sales Growth 4.5 Europe Inhaled Medicines for Respiratory System Sales Growth 4.6 Middle East & Africa Inhaled Medicines for Respiratory System Sales Growth 5 Americas 5.1 Americas Inhaled Medicines for Respiratory System Sales by Country 5.1.1 Americas Inhaled Medicines for Respiratory System Sales by Country (2021-2026) 5.1.2 Americas Inhaled Medicines for Respiratory System Revenue by Country (2021-2026) 5.2 Americas Inhaled Medicines for Respiratory System Sales by Type (2021-2026) 5.3 Americas Inhaled Medicines for Respiratory System Sales by Application (2021-2026) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Inhaled Medicines for Respiratory System Sales by Region 6.1.1 APAC Inhaled Medicines for Respiratory System Sales by Region (2021-2026) 6.1.2 APAC Inhaled Medicines for Respiratory System Revenue by Region (2021-2026) 6.2 APAC Inhaled Medicines for Respiratory System Sales by Type (2021-2026) 6.3 APAC Inhaled Medicines for Respiratory System Sales by Application (2021-2026) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Inhaled Medicines for Respiratory System by Country 7.1.1 Europe Inhaled Medicines for Respiratory System Sales by Country (2021-2026) 7.1.2 Europe Inhaled Medicines for Respiratory System Revenue by Country (2021-2026) 7.2 Europe Inhaled Medicines for Respiratory System Sales by Type (2021-2026) 7.3 Europe Inhaled Medicines for Respiratory System Sales by Application (2021-2026) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Inhaled Medicines for Respiratory System by Country 8.1.1 Middle East & Africa Inhaled Medicines for Respiratory System Sales by Country (2021-2026) 8.1.2 Middle East & Africa Inhaled Medicines for Respiratory System Revenue by Country (2021-2026) 8.2 Middle East & Africa Inhaled Medicines for Respiratory System Sales by Type (2021-2026) 8.3 Middle East & Africa Inhaled Medicines for Respiratory System Sales by Application (2021-2026) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Inhaled Medicines for Respiratory System 10.3 Manufacturing Process Analysis of Inhaled Medicines for Respiratory System 10.4 Industry Chain Structure of Inhaled Medicines for Respiratory System 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Inhaled Medicines for Respiratory System Distributors 11.3 Inhaled Medicines for Respiratory System Customer 12 World Forecast Review for Inhaled Medicines for Respiratory System by Geographic Region 12.1 Global Inhaled Medicines for Respiratory System Market Size Forecast by Region 12.1.1 Global Inhaled Medicines for Respiratory System Forecast by Region (2027-2032) 12.1.2 Global Inhaled Medicines for Respiratory System Annual Revenue Forecast by Region (2027-2032) 12.2 Americas Forecast by Country (2027-2032) 12.3 APAC Forecast by Region (2027-2032) 12.4 Europe Forecast by Country (2027-2032) 12.5 Middle East & Africa Forecast by Country (2027-2032) 12.6 Global Inhaled Medicines for Respiratory System Forecast by Type (2027-2032) 12.7 Global Inhaled Medicines for Respiratory System Forecast by Application (2027-2032) 13 Key Players Analysis 13.1 Boehringer Ingelheim 13.1.1 Boehringer Ingelheim Company Information 13.1.2 Boehringer Ingelheim Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.1.3 Boehringer Ingelheim Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.1.4 Boehringer Ingelheim Main Business Overview 13.1.5 Boehringer Ingelheim Latest Developments 13.2 GSK 13.2.1 GSK Company Information 13.2.2 GSK Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.2.3 GSK Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.2.4 GSK Main Business Overview 13.2.5 GSK Latest Developments 13.3 Teva Pharmaceutical 13.3.1 Teva Pharmaceutical Company Information 13.3.2 Teva Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.3.3 Teva Pharmaceutical Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.3.4 Teva Pharmaceutical Main Business Overview 13.3.5 Teva Pharmaceutical Latest Developments 13.4 Prasco Laboratories 13.4.1 Prasco Laboratories Company Information 13.4.2 Prasco Laboratories Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.4.3 Prasco Laboratories Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.4.4 Prasco Laboratories Main Business Overview 13.4.5 Prasco Laboratories Latest Developments 13.5 Cipla 13.5.1 Cipla Company Information 13.5.2 Cipla Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.5.3 Cipla Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.5.4 Cipla Main Business Overview 13.5.5 Cipla Latest Developments 13.6 Lupin Laboratories 13.6.1 Lupin Laboratories Company Information 13.6.2 Lupin Laboratories Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.6.3 Lupin Laboratories Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.6.4 Lupin Laboratories Main Business Overview 13.6.5 Lupin Laboratories Latest Developments 13.7 Laboratorio Aldo-Union 13.7.1 Laboratorio Aldo-Union Company Information 13.7.2 Laboratorio Aldo-Union Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.7.3 Laboratorio Aldo-Union Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.7.4 Laboratorio Aldo-Union Main Business Overview 13.7.5 Laboratorio Aldo-Union Latest Developments 13.8 Polpharma 13.8.1 Polpharma Company Information 13.8.2 Polpharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.8.3 Polpharma Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.8.4 Polpharma Main Business Overview 13.8.5 Polpharma Latest Developments 13.9 Novartis 13.9.1 Novartis Company Information 13.9.2 Novartis Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.9.3 Novartis Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.9.4 Novartis Main Business Overview 13.9.5 Novartis Latest Developments 13.10 The Menarini Group 13.10.1 The Menarini Group Company Information 13.10.2 The Menarini Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.10.3 The Menarini Group Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.10.4 The Menarini Group Main Business Overview 13.10.5 The Menarini Group Latest Developments 13.11 Covis Pharma 13.11.1 Covis Pharma Company Information 13.11.2 Covis Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.11.3 Covis Pharma Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.11.4 Covis Pharma Main Business Overview 13.11.5 Covis Pharma Latest Developments 13.12 Zentiva 13.12.1 Zentiva Company Information 13.12.2 Zentiva Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.12.3 Zentiva Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.12.4 Zentiva Main Business Overview 13.12.5 Zentiva Latest Developments 13.13 Alfasigma 13.13.1 Alfasigma Company Information 13.13.2 Alfasigma Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.13.3 Alfasigma Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.13.4 Alfasigma Main Business Overview 13.13.5 Alfasigma Latest Developments 13.14 Gebro-Pharma 13.14.1 Gebro-Pharma Company Information 13.14.2 Gebro-Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.14.3 Gebro-Pharma Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.14.4 Gebro-Pharma Main Business Overview 13.14.5 Gebro-Pharma Latest Developments 13.15 Kohl Medical 13.15.1 Kohl Medical Company Information 13.15.2 Kohl Medical Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.15.3 Kohl Medical Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.15.4 Kohl Medical Main Business Overview 13.15.5 Kohl Medical Latest Developments 13.16 Sumitomo Pharma 13.16.1 Sumitomo Pharma Company Information 13.16.2 Sumitomo Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.16.3 Sumitomo Pharma Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.16.4 Sumitomo Pharma Main Business Overview 13.16.5 Sumitomo Pharma Latest Developments 13.17 Chiesi Farmaceutici 13.17.1 Chiesi Farmaceutici Company Information 13.17.2 Chiesi Farmaceutici Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.17.3 Chiesi Farmaceutici Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.17.4 Chiesi Farmaceutici Main Business Overview 13.17.5 Chiesi Farmaceutici Latest Developments 13.18 Glenmark Pharmaceuticals 13.18.1 Glenmark Pharmaceuticals Company Information 13.18.2 Glenmark Pharmaceuticals Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.18.3 Glenmark Pharmaceuticals Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.18.4 Glenmark Pharmaceuticals Main Business Overview 13.18.5 Glenmark Pharmaceuticals Latest Developments 13.19 Orion Corporation 13.19.1 Orion Corporation Company Information 13.19.2 Orion Corporation Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.19.3 Orion Corporation Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.19.4 Orion Corporation Main Business Overview 13.19.5 Orion Corporation Latest Developments 13.20 Bausch Health 13.20.1 Bausch Health Company Information 13.20.2 Bausch Health Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.20.3 Bausch Health Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.20.4 Bausch Health Main Business Overview 13.20.5 Bausch Health Latest Developments 13.21 Viatris 13.21.1 Viatris Company Information 13.21.2 Viatris Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.21.3 Viatris Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.21.4 Viatris Main Business Overview 13.21.5 Viatris Latest Developments 13.22 AstraZeneca 13.22.1 AstraZeneca Company Information 13.22.2 AstraZeneca Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.22.3 AstraZeneca Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.22.4 AstraZeneca Main Business Overview 13.22.5 AstraZeneca Latest Developments 13.23 LEK-AM 13.23.1 LEK-AM Company Information 13.23.2 LEK-AM Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.23.3 LEK-AM Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.23.4 LEK-AM Main Business Overview 13.23.5 LEK-AM Latest Developments 13.24 Adamed Group 13.24.1 Adamed Group Company Information 13.24.2 Adamed Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.24.3 Adamed Group Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.24.4 Adamed Group Main Business Overview 13.24.5 Adamed Group Latest Developments 13.25 STADA Arzneimittel 13.25.1 STADA Arzneimittel Company Information 13.25.2 STADA Arzneimittel Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.25.3 STADA Arzneimittel Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.25.4 STADA Arzneimittel Main Business Overview 13.25.5 STADA Arzneimittel Latest Developments 13.26 Organon 13.26.1 Organon Company Information 13.26.2 Organon Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.26.3 Organon Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.26.4 Organon Main Business Overview 13.26.5 Organon Latest Developments 13.27 Anhui Wellman Pharmaceutical 13.27.1 Anhui Wellman Pharmaceutical Company Information 13.27.2 Anhui Wellman Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.27.3 Anhui Wellman Pharmaceutical Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.27.4 Anhui Wellman Pharmaceutical Main Business Overview 13.27.5 Anhui Wellman Pharmaceutical Latest Developments 13.28 Zhejiang Xianjun Pharmaceutical 13.28.1 Zhejiang Xianjun Pharmaceutical Company Information 13.28.2 Zhejiang Xianjun Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.28.3 Zhejiang Xianjun Pharmaceutical Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.28.4 Zhejiang Xianjun Pharmaceutical Main Business Overview 13.28.5 Zhejiang Xianjun Pharmaceutical Latest Developments 13.29 Chia Tai Tianqing Pharmaceutical Group 13.29.1 Chia Tai Tianqing Pharmaceutical Group Company Information 13.29.2 Chia Tai Tianqing Pharmaceutical Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.29.3 Chia Tai Tianqing Pharmaceutical Group Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.29.4 Chia Tai Tianqing Pharmaceutical Group Main Business Overview 13.29.5 Chia Tai Tianqing Pharmaceutical Group Latest Developments 13.30 Nanchang Helioeast Technology 13.30.1 Nanchang Helioeast Technology Company Information 13.30.2 Nanchang Helioeast Technology Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.30.3 Nanchang Helioeast Technology Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.30.4 Nanchang Helioeast Technology Main Business Overview 13.30.5 Nanchang Helioeast Technology Latest Developments 13.31 Jewim Pharmaceutical 13.31.1 Jewim Pharmaceutical Company Information 13.31.2 Jewim Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.31.3 Jewim Pharmaceutical Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.31.4 Jewim Pharmaceutical Main Business Overview 13.31.5 Jewim Pharmaceutical Latest Developments 13.32 Heilongjiang Fulekang Pharmaceutical 13.32.1 Heilongjiang Fulekang Pharmaceutical Company Information 13.32.2 Heilongjiang Fulekang Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.32.3 Heilongjiang Fulekang Pharmaceutical Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.32.4 Heilongjiang Fulekang Pharmaceutical Main Business Overview 13.32.5 Heilongjiang Fulekang Pharmaceutical Latest Developments 13.33 Shanghai Pharmaceuticals 13.33.1 Shanghai Pharmaceuticals Company Information 13.33.2 Shanghai Pharmaceuticals Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.33.3 Shanghai Pharmaceuticals Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.33.4 Shanghai Pharmaceuticals Main Business Overview 13.33.5 Shanghai Pharmaceuticals Latest Developments 13.34 Lunan Better Pharmaceutical 13.34.1 Lunan Better Pharmaceutical Company Information 13.34.2 Lunan Better Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.34.3 Lunan Better Pharmaceutical Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.34.4 Lunan Better Pharmaceutical Main Business Overview 13.34.5 Lunan Better Pharmaceutical Latest Developments 13.35 China Resources Double Crane Pharmaceutical 13.35.1 China Resources Double Crane Pharmaceutical Company Information 13.35.2 China Resources Double Crane Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications 13.35.3 China Resources Double Crane Pharmaceutical Inhaled Medicines for Respiratory System Sales, Revenue, Price and Gross Margin (2021-2026) 13.35.4 China Resources Double Crane Pharmaceutical Main Business Overview 13.35.5 China Resources Double Crane Pharmaceutical Latest Developments 14 Research Findings and Conclusion List of Tables/GraphsList of TablesTable 1. Inhaled Medicines for Respiratory System Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions) Table 2. Inhaled Medicines for Respiratory System Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions) Table 3. Major Players of Inhaled Corticosteroids Table 4. Major Players of Long-acting Bronchodilators Table 5. Major Players of Short-acting Bronchodilators Table 6. Major Players of Combination Medications Table 7. Global Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 8. Global Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) Table 9. Global Inhaled Medicines for Respiratory System Revenue by Type (2021-2026) & ($ million) Table 10. Global Inhaled Medicines for Respiratory System Revenue Market Share by Type (2021-2026) Table 11. Global Inhaled Medicines for Respiratory System Sale Price by Type (2021-2026) & (US$/Unit) Table 12. Global Inhaled Medicines for Respiratory System Sale by Application (2021-2026) & (K Units) Table 13. Global Inhaled Medicines for Respiratory System Sale Market Share by Application (2021-2026) Table 14. Global Inhaled Medicines for Respiratory System Revenue by Application (2021-2026) & ($ million) Table 15. Global Inhaled Medicines for Respiratory System Revenue Market Share by Application (2021-2026) Table 16. Global Inhaled Medicines for Respiratory System Sale Price by Application (2021-2026) & (US$/Unit) Table 17. Global Inhaled Medicines for Respiratory System Sales by Company (2021-2026) & (K Units) Table 18. Global Inhaled Medicines for Respiratory System Sales Market Share by Company (2021-2026) Table 19. Global Inhaled Medicines for Respiratory System Revenue by Company (2021-2026) & ($ millions) Table 20. Global Inhaled Medicines for Respiratory System Revenue Market Share by Company (2021-2026) Table 21. Global Inhaled Medicines for Respiratory System Sale Price by Company (2021-2026) & (US$/Unit) Table 22. Key Manufacturers Inhaled Medicines for Respiratory System Producing Area Distribution and Sales Area Table 23. Players Inhaled Medicines for Respiratory System Products Offered Table 24. Inhaled Medicines for Respiratory System Concentration Ratio (CR3, CR5 and CR10) & (2024-2026) Table 25. New Products and Potential Entrants Table 26. Market M&A Activity & Strategy Table 27. Global Inhaled Medicines for Respiratory System Sales by Geographic Region (2021-2026) & (K Units) Table 28. Global Inhaled Medicines for Respiratory System Sales Market Share Geographic Region (2021-2026) Table 29. Global Inhaled Medicines for Respiratory System Revenue by Geographic Region (2021-2026) & ($ millions) Table 30. Global Inhaled Medicines for Respiratory System Revenue Market Share by Geographic Region (2021-2026) Table 31. Global Inhaled Medicines for Respiratory System Sales by Country/Region (2021-2026) & (K Units) Table 32. Global Inhaled Medicines for Respiratory System Sales Market Share by Country/Region (2021-2026) Table 33. Global Inhaled Medicines for Respiratory System Revenue by Country/Region (2021-2026) & ($ millions) Table 34. Global Inhaled Medicines for Respiratory System Revenue Market Share by Country/Region (2021-2026) Table 35. Americas Inhaled Medicines for Respiratory System Sales by Country (2021-2026) & (K Units) Table 36. Americas Inhaled Medicines for Respiratory System Sales Market Share by Country (2021-2026) Table 37. Americas Inhaled Medicines for Respiratory System Revenue by Country (2021-2026) & ($ millions) Table 38. Americas Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 39. Americas Inhaled Medicines for Respiratory System Sales by Application (2021-2026) & (K Units) Table 40. APAC Inhaled Medicines for Respiratory System Sales by Region (2021-2026) & (K Units) Table 41. APAC Inhaled Medicines for Respiratory System Sales Market Share by Region (2021-2026) Table 42. APAC Inhaled Medicines for Respiratory System Revenue by Region (2021-2026) & ($ millions) Table 43. APAC Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 44. APAC Inhaled Medicines for Respiratory System Sales by Application (2021-2026) & (K Units) Table 45. Europe Inhaled Medicines for Respiratory System Sales by Country (2021-2026) & (K Units) Table 46. Europe Inhaled Medicines for Respiratory System Revenue by Country (2021-2026) & ($ millions) Table 47. Europe Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 48. Europe Inhaled Medicines for Respiratory System Sales by Application (2021-2026) & (K Units) Table 49. Middle East & Africa Inhaled Medicines for Respiratory System Sales by Country (2021-2026) & (K Units) Table 50. Middle East & Africa Inhaled Medicines for Respiratory System Revenue Market Share by Country (2021-2026) Table 51. Middle East & Africa Inhaled Medicines for Respiratory System Sales by Type (2021-2026) & (K Units) Table 52. Middle East & Africa Inhaled Medicines for Respiratory System Sales by Application (2021-2026) & (K Units) Table 53. Key Market Drivers & Growth Opportunities of Inhaled Medicines for Respiratory System Table 54. Key Market Challenges & Risks of Inhaled Medicines for Respiratory System Table 55. Key Industry Trends of Inhaled Medicines for Respiratory System Table 56. Inhaled Medicines for Respiratory System Raw Material Table 57. Key Suppliers of Raw Materials Table 58. Inhaled Medicines for Respiratory System Distributors List Table 59. Inhaled Medicines for Respiratory System Customer List Table 60. Global Inhaled Medicines for Respiratory System Sales Forecast by Region (2027-2032) & (K Units) Table 61. Global Inhaled Medicines for Respiratory System Revenue Forecast by Region (2027-2032) & ($ millions) Table 62. Americas Inhaled Medicines for Respiratory System Sales Forecast by Country (2027-2032) & (K Units) Table 63. Americas Inhaled Medicines for Respiratory System Annual Revenue Forecast by Country (2027-2032) & ($ millions) Table 64. APAC Inhaled Medicines for Respiratory System Sales Forecast by Region (2027-2032) & (K Units) Table 65. APAC Inhaled Medicines for Respiratory System Annual Revenue Forecast by Region (2027-2032) & ($ millions) Table 66. Europe Inhaled Medicines for Respiratory System Sales Forecast by Country (2027-2032) & (K Units) Table 67. Europe Inhaled Medicines for Respiratory System Revenue Forecast by Country (2027-2032) & ($ millions) Table 68. Middle East & Africa Inhaled Medicines for Respiratory System Sales Forecast by Country (2027-2032) & (K Units) Table 69. Middle East & Africa Inhaled Medicines for Respiratory System Revenue Forecast by Country (2027-2032) & ($ millions) Table 70. Global Inhaled Medicines for Respiratory System Sales Forecast by Type (2027-2032) & (K Units) Table 71. Global Inhaled Medicines for Respiratory System Revenue Forecast by Type (2027-2032) & ($ millions) Table 72. Global Inhaled Medicines for Respiratory System Sales Forecast by Application (2027-2032) & (K Units) Table 73. Global Inhaled Medicines for Respiratory System Revenue Forecast by Application (2027-2032) & ($ millions) Table 74. Boehringer Ingelheim Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 75. Boehringer Ingelheim Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 76. Boehringer Ingelheim Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Boehringer Ingelheim Main Business Table 78. Boehringer Ingelheim Latest Developments Table 79. GSK Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 80. GSK Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 81. GSK Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. GSK Main Business Table 83. GSK Latest Developments Table 84. Teva Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 85. Teva Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 86. Teva Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Teva Pharmaceutical Main Business Table 88. Teva Pharmaceutical Latest Developments Table 89. Prasco Laboratories Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 90. Prasco Laboratories Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 91. Prasco Laboratories Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Prasco Laboratories Main Business Table 93. Prasco Laboratories Latest Developments Table 94. Cipla Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 95. Cipla Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 96. Cipla Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Cipla Main Business Table 98. Cipla Latest Developments Table 99. Lupin Laboratories Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 100. Lupin Laboratories Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 101. Lupin Laboratories Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Lupin Laboratories Main Business Table 103. Lupin Laboratories Latest Developments Table 104. Laboratorio Aldo-Union Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 105. Laboratorio Aldo-Union Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 106. Laboratorio Aldo-Union Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Laboratorio Aldo-Union Main Business Table 108. Laboratorio Aldo-Union Latest Developments Table 109. Polpharma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 110. Polpharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 111. Polpharma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Polpharma Main Business Table 113. Polpharma Latest Developments Table 114. Novartis Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 115. Novartis Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 116. Novartis Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Novartis Main Business Table 118. Novartis Latest Developments Table 119. The Menarini Group Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 120. The Menarini Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 121. The Menarini Group Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. The Menarini Group Main Business Table 123. The Menarini Group Latest Developments Table 124. Covis Pharma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 125. Covis Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 126. Covis Pharma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Covis Pharma Main Business Table 128. Covis Pharma Latest Developments Table 129. Zentiva Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 130. Zentiva Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 131. Zentiva Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Zentiva Main Business Table 133. Zentiva Latest Developments Table 134. Alfasigma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 135. Alfasigma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 136. Alfasigma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Alfasigma Main Business Table 138. Alfasigma Latest Developments Table 139. Gebro-Pharma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 140. Gebro-Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 141. Gebro-Pharma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Gebro-Pharma Main Business Table 143. Gebro-Pharma Latest Developments Table 144. Kohl Medical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 145. Kohl Medical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 146. Kohl Medical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Kohl Medical Main Business Table 148. Kohl Medical Latest Developments Table 149. Sumitomo Pharma Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 150. Sumitomo Pharma Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 151. Sumitomo Pharma Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Sumitomo Pharma Main Business Table 153. Sumitomo Pharma Latest Developments Table 154. Chiesi Farmaceutici Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 155. Chiesi Farmaceutici Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 156. Chiesi Farmaceutici Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Chiesi Farmaceutici Main Business Table 158. Chiesi Farmaceutici Latest Developments Table 159. Glenmark Pharmaceuticals Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 160. Glenmark Pharmaceuticals Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 161. Glenmark Pharmaceuticals Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Glenmark Pharmaceuticals Main Business Table 163. Glenmark Pharmaceuticals Latest Developments Table 164. Orion Corporation Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 165. Orion Corporation Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 166. Orion Corporation Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Orion Corporation Main Business Table 168. Orion Corporation Latest Developments Table 169. Bausch Health Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 170. Bausch Health Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 171. Bausch Health Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Bausch Health Main Business Table 173. Bausch Health Latest Developments Table 174. Viatris Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 175. Viatris Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 176. Viatris Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Viatris Main Business Table 178. Viatris Latest Developments Table 179. AstraZeneca Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 180. AstraZeneca Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 181. AstraZeneca Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. AstraZeneca Main Business Table 183. AstraZeneca Latest Developments Table 184. LEK-AM Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 185. LEK-AM Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 186. LEK-AM Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 187. LEK-AM Main Business Table 188. LEK-AM Latest Developments Table 189. Adamed Group Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 190. Adamed Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 191. Adamed Group Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 192. Adamed Group Main Business Table 193. Adamed Group Latest Developments Table 194. STADA Arzneimittel Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 195. STADA Arzneimittel Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 196. STADA Arzneimittel Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 197. STADA Arzneimittel Main Business Table 198. STADA Arzneimittel Latest Developments Table 199. Organon Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 200. Organon Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 201. Organon Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 202. Organon Main Business Table 203. Organon Latest Developments Table 204. Anhui Wellman Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 205. Anhui Wellman Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 206. Anhui Wellman Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 207. Anhui Wellman Pharmaceutical Main Business Table 208. Anhui Wellman Pharmaceutical Latest Developments Table 209. Zhejiang Xianjun Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 210. Zhejiang Xianjun Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 211. Zhejiang Xianjun Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 212. Zhejiang Xianjun Pharmaceutical Main Business Table 213. Zhejiang Xianjun Pharmaceutical Latest Developments Table 214. Chia Tai Tianqing Pharmaceutical Group Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 215. Chia Tai Tianqing Pharmaceutical Group Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 216. Chia Tai Tianqing Pharmaceutical Group Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 217. Chia Tai Tianqing Pharmaceutical Group Main Business Table 218. Chia Tai Tianqing Pharmaceutical Group Latest Developments Table 219. Nanchang Helioeast Technology Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 220. Nanchang Helioeast Technology Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 221. Nanchang Helioeast Technology Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 222. Nanchang Helioeast Technology Main Business Table 223. Nanchang Helioeast Technology Latest Developments Table 224. Jewim Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 225. Jewim Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 226. Jewim Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 227. Jewim Pharmaceutical Main Business Table 228. Jewim Pharmaceutical Latest Developments Table 229. Heilongjiang Fulekang Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 230. Heilongjiang Fulekang Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 231. Heilongjiang Fulekang Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 232. Heilongjiang Fulekang Pharmaceutical Main Business Table 233. Heilongjiang Fulekang Pharmaceutical Latest Developments Table 234. Shanghai Pharmaceuticals Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 235. Shanghai Pharmaceuticals Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 236. Shanghai Pharmaceuticals Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 237. Shanghai Pharmaceuticals Main Business Table 238. Shanghai Pharmaceuticals Latest Developments Table 239. Lunan Better Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 240. Lunan Better Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 241. Lunan Better Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 242. Lunan Better Pharmaceutical Main Business Table 243. Lunan Better Pharmaceutical Latest Developments Table 244. China Resources Double Crane Pharmaceutical Basic Information, Inhaled Medicines for Respiratory System Manufacturing Base, Sales Area and Its Competitors Table 245. China Resources Double Crane Pharmaceutical Inhaled Medicines for Respiratory System Product Portfolios and Specifications Table 246. China Resources Double Crane Pharmaceutical Inhaled Medicines for Respiratory System Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 247. China Resources Double Crane Pharmaceutical Main Business Table 248. China Resources Double Crane Pharmaceutical Latest Developments List of Figures Figure 1. Picture of Inhaled Medicines for Respiratory System Figure 2. Inhaled Medicines for Respiratory System Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Inhaled Medicines for Respiratory System Sales Growth Rate 2021-2032 (K Units) Figure 7. Global Inhaled Medicines for Respiratory System Revenue Growth Rate 2021-2032 ($ millions) Figure 8. Inhaled Medicines for Respiratory System Sales by Geographic Region (2021, 2025 & 2032) & ($ millions) Figure 9. Inhaled Medicines for Respiratory System Sales Market Share by Country/Region (2025) Figure 10. Inhaled Medicines for Respiratory System Sales Market Share by Country/Region (2021, 2025 & 2032) Figure 11. Product Picture of Inhaled Corticosteroids Figure 12. Product Picture of Long-acting Bronchodilators Figure 13. Product Picture of Short-acting Bronchodilators Figure 14. Product Picture of Combination Medications Figure 15. Global Inhaled Medicines for Respiratory System Sales Market Share by Type in 2026 Figure 16. Global Inhaled Medicines for Respiratory System Revenue Market Share by Type (2021-2026) Figure 17. Inhaled Medicines for Respiratory System Consumed in Asthma Figure 18. Global Inhaled Medicines for Respiratory System Market: Asthma (2021-2026) & (K Units) Figure 19. Inhaled Medicines for Respiratory System Consumed in COPD Figure 20. Global Inhaled Medicines for Respiratory System Market: COPD (2021-2026) & (K Units) Figure 21. Inhaled Medicines for Respiratory System Consumed in Others Figure 22. Global Inhaled Medicines for Respiratory System Market: Others (2021-2026) & (K Units) Figure 23. Global Inhaled Medicines for Respiratory System Sale Market Share by Application (2025) Figure 24. Global Inhaled Medicines for Respiratory System Revenue Market Share by Application in 2026 Figure 25. Inhaled Medicines for Respiratory System Sales by Company in 2026 (K Units) Figure 26. Global Inhaled Medicines for Respiratory System Sales Market Share by Company in 2026 Figure 27. Inhaled Medicines for Respiratory System Revenue by Company in 2026 ($ millions) Figure 28. Global Inhaled Medicines for Respiratory System Revenue Market Share by Company in 2026 Figure 29. Global Inhaled Medicines for Respiratory System Sales Market Share by Geographic Region (2021-2026) Figure 30. Global Inhaled Medicines for Respiratory System Revenue Market Share by Geographic Region in 2026 Figure 31. Americas Inhaled Medicines for Respiratory System Sales 2021-2026 (K Units) Figure 32. Americas Inhaled Medicines for Respiratory System Revenue 2021-2026 ($ millions) Figure 33. APAC Inhaled Medicines for Respiratory System Sales 2021-2026 (K Units) Figure 34. APAC Inhaled Medicines for Respiratory System Revenue 2021-2026 ($ millions) Figure 35. Europe Inhaled Medicines for Respiratory System Sales 2021-2026 (K Units) Figure 36. Europe Inhaled Medicines for Respiratory System Revenue 2021-2026 ($ millions) Figure 37. Middle East & Africa Inhaled Medicines for Respiratory System Sales 2021-2026 (K Units) Figure 38. Middle East & Africa Inhaled Medicines for Respiratory System Revenue 2021-2026 ($ millions) Figure 39. Americas Inhaled Medicines for Respiratory System Sales Market Share by Country in 2026 Figure 40. Americas Inhaled Medicines for Respiratory System Revenue Market Share by Country (2021-2026) Figure 41. Americas Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) Figure 42. Americas Inhaled Medicines for Respiratory System Sales Market Share by Application (2021-2026) Figure 43. United States Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 44. Canada Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 45. Mexico Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 46. Brazil Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 47. APAC Inhaled Medicines for Respiratory System Sales Market Share by Region in 2026 Figure 48. APAC Inhaled Medicines for Respiratory System Revenue Market Share by Region (2021-2026) Figure 49. APAC Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) Figure 50. APAC Inhaled Medicines for Respiratory System Sales Market Share by Application (2021-2026) Figure 51. China Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 52. Japan Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 53. South Korea Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 54. Southeast Asia Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 55. India Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 56. Australia Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 57. China Taiwan Inhaled Medicines for Respiratory System Revenue Growth 2021-2026 ($ millions) Figure 58. Europe Inhaled Medicines for Respiratory System Sales Market Share by Country in 2026 Figure 59. Europe Inhaled Medicines for Respiratory System Revenue Market Share by Country (2021-2026) Figure 60. Europe Inhaled Medicines for Respiratory System Sales Market Share by Type (2021-2026) Figure 61. Europe Inhaled Medicines for Respiratory System Sales Market Share by Application (2021-2026)
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
LP Information社の 医薬品・ヘルスケア分野 での最新刊レポート
本レポートと同じKEY WORD（respiratory）の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
